WCN23-0246 THE APPLICATION OF ARTIFICIAL INTELLIGENCE-BASED ANALYTIC RENAL PATHOLOGY SYSTEM IN MCD, FSGS, AND MN

Abstract

1.212 (if Black)].A total of 5 mean eGFR values were obtained and analyzed: the mean eGFR between 1 and 2 years before initiation of DAA therapy was recorded as GFR 1; the mean eGFR within one year before DAA treatment was defined as GFR 2 (baseline eGFR); GFR 3 was the mean eGFR between initiation of DAA and 12 weeks after the end of DAA treatment; GFR 4 was the mean eGFR between 12 and 28 weeks after the end of DAA treatment; GFR 5 was the mean eGFR between 28 weeks and 1 year and 28 weeks after the end of DAA treatment.Individuals with missing any one of GFR 1 through GFR 5 were excluded from the analysis.We used mixed effect model to examine the difference in eGFR over time between individuals who received sofosbuvirbased or sofosbuvir-free DAA.Results: A total of 32093 DAA treated HCV patients were included; 51.8% (16634 individuals) received sofosbuvir-based and 48.2% (15459 individuals) received sofosbuvir-free DAAs.Among the 32093 individuals, 38.1% and 55.4% were aged 45-64 and above 65 years, respectively, and 47.1% were male.In the total study population, patients receiving sofosbuvir-free DAA regimens were associated with 0.67 ml/min/1.73m 2 (p < 0.0001) lower in eGFR over the 2-year follow-up compared with those who received sofosbuvirbased DAA by using mixed effect model adjusting for age, sex, baseline eGFR, eGFR slope before DAA therapy, and DAA course length.When stratified by eGFR categories, our results showed that there was no difference in eGFR over time between sofosbuvir-based or sofosbuvir-free groups among those with baseline eGFR > 90 and 60-89 ml/min/1.73m 2 .However, among individuals with baseline eGFR 30-59 and < 30 ml/min/1.73m 2 , individuals with sofosbuvirfree DAA regimens were associated with 0.46 ml/min/1.73m 2 (p < 0.05) and 1.24 ml/min/1.73m 2 (p < 0.0001) lower in eGFR over the 2-year follow-up when compared with those who received sofosbuvir-based DAA.Conclusions: HCV patients receiving sofosbuvir-based DAA regimens are associated with slower decline in kidney function in those with reduced kidney function, particularly for those with baseline eGFR lower than 30 ml/min/1.73m 2 .No conflict of interest

Ähnliche Arbeiten